Brief Title
Estrogen Treatment in Acromegalic Women
Brief Summary
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
Detailed Description
This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.
Study Phase
Phase 2
Study Type
Interventional
Condition
Acromegaly
Intervention
Alesse
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
30
Start Date
May 2006
Completion Date
August 2007
Eligibility Criteria
Inclusion Criteria: - Women 18 years and older treated with somatostatin analogs - Active acromegaly Exclusion Criteria: - Cardiovascular or cerebrovascular disease - Thrombophlebitis or thromboembolism - Breast cancer - Non-controlled arterial hypertension - Smoking - Pregnancy or lactation
Gender
Female
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Omar Serri, MD, 514-890-8000, [email protected]
Location Countries
Canada
Location Countries
Canada
Administrative Informations
NCT ID
NCT00315107
Organization ID
HND01
Study Sponsor
Université de Montréal
Collaborators
Novartis
Study Sponsor
Omar Serri, MD, Principal Investigator, CHUM- Endocrinology
Verification Date
May 2006